Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers

BACKGROUND: Vascular endothelial growth factor inhibitors (VEGFi) are compromised by a lack of validated biomarkers. Previously we showed that changes in the concentration of plasma Tie2 (pTie2) was a response biomarker for bevacizumab. Here, we investigated whether pTie2 can predict response and pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, C., O’Connor, J., Backen, A., Valle, J.W., Bridgewater, J., Dive, C., Jayson, G.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058891/
https://www.ncbi.nlm.nih.gov/pubmed/35279528
http://dx.doi.org/10.1016/j.esmoop.2022.100417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058891/
https://www.ncbi.nlm.nih.gov/pubmed/35279528
http://dx.doi.org/10.1016/j.esmoop.2022.100417

Ejemplares similares